Hormone replacement therapy in the menopause: A pro opinion

Ca-A Cancer Journal for Clinicians

Volumn 46, Issue 6, 1996, Pages 343-363

  Smith, Harriet O ^a   Kammerer Doak, Dorothy N ^a   Barbo, Dorothy M ^a   Sarto, Gloria E ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTROGEN; GESTAGEN; TAMOXIFEN;

ADULT; ALCOHOL CONSUMPTION; BODY WEIGHT; BONE MASS; BREAST CANCER; BREAST FEEDING; CALCIUM INTAKE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG SAFETY; ESTROGEN THERAPY; EXERCISE; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE; LIMB FRACTURE; MAJOR CLINICAL STUDY; MENOPAUSE; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; STROKE;

EID: 0029846094     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.46.6.343     Document Type: Review

References (152)

1. U.S. Bureau of the Census: Statistical Abstract of the United States: 1993 (113th edition). Washington, DC, Government Printing Office, 1993.
2. American College of Obstetricians and Gynecologists: Hormone Replacement Therapy (Technical Bulletin No. 166). Washington D.C., ACOG, April 1992.
3. Grady D, Rubin SM, Petitti DB, et al: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.
4. Bush TL: The epidemiology of cardiovascular disease in older persons. Aging 1991;3:3-8.
5. Lerner DJ, Kannel WB: Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J 1986;111:383-390.
6. Jensen J: Effects of sex steroids on serum lipids and lipoproteins. Baillieres Clin Obstet Gynaecol 1991;5:867-887.
7. Burkman RT: Lipid and lipoprolein changes in relation to oral contraception and hormonal replacement therapy. Fertil Steril 1988;49(suppl 2):39S-50S.
8. Tikkanen M, Nikkila E: Menopause, estrogens and risk for coronary heart disease. Acta Obstel Gynecol Scand Suppl 1987;140:39-45.
9. Walsh BW, Schiff I, Rosner B, et al: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-1204.
10. Miller VT, Muesing RA, LaRosa JC, et al: Quantitative and qualitative changes in lipids, lipoproteins, apolipoprotein A-I, and sex hormone- binding globulin due to two doses of conjugated equine estrogen with and without a progestin. Obstet Gynecol 1994;83:173-179.
11. Bush TL, Barrett-Connor E, Cowan LD, et al: Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-1109.
12. Gambrell RD Jr, Teran AZ: Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy. Am J Obstet Gynecol 1991;165:307-317.
13. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
14. Smith RN, Studd JW: Recent advances in hormone replacement therapy. Br J Hosp Med 1993;49:799-808.
15. Reis SE, Goth ST, Blumenthal RS, et al: Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994;89:52-60.
16. Gilligan DM, Badar DM, Panza JA, et al. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994;90:786-791.
17. Bush TL: Noncontraceptive estrogen use and risk of cardiovascular disease: An overview and critique of the literature, in Korenman SG (ed): The Menopause: Biological and Clinical Consequences of Ovarian Failure: Evolution and Management. Norwell, Mass, Sereno Symposia; 1990, pp 211-223.
18. Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
19. Henderson BE, Paganini-Hill A, Ross RK: Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988;159:312-317.
20. Henderson BE, Paganini-Hill A, Ross RK: Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-78.
21. Stampfer MJ, Colditz GA, Willett WC, et al: Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the nurses' health study. N Engl J Med 1991;325:756-762.
22. Sullivan JM, Vander Zwaag R, Hughes JP, et al: Estrogen replacement and coronary artery disease: Effect on survival in postmenopausal women. Arch Intern Med 1990;150:2557-2562.
23. Tikkanen MJ, Kuusi T, Nikkila EA, Sipinen S: Post-menopausal hormone replacement therapy: Effects of progestogens on serum lipids and lipoproteins: A review. Maturitas 1986;8:7-17.
24. Falkeborn M, Persson I, Adami HO, et al: The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821-828.
25. Nabulsi AA, Folsom AR, While A, et al: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069-1075.
26. Consensus Conference: Osteoporosis. JAMA 1984;252:799-802.
27. Rodriguez JG, Sattin RW, Waxweiler RJ: Incidence of hip fractures. United States, 1970- 1983. Am J Prev Med 1989;5:175-181.
28. Henderson BE, Ross RK, Lobo RA, et al: Re-evaluating the role of progestogen therapy after the menopause. Fertil Steril 1988;49(suppl 2):9S-15S.
29. Whitcroft SIJ, Stevenson JC: Hormone replacement therapy: Risks and benefits; Clin Endocrinol 1992;36:15-20.
30. Lindsay R: Estrogen therapy in the prevention and management of osteoporosis. Am J Obstet Gynecol 1987;156:1347-1351.
31. Kiel DP, Felson DT, Anderson JJ, et al: Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 1987;317:1169-1174.
32. Weiss NS, Ure CL, Ballard JH, et al: Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-1198.
33. Holland EF, Studd JW, Mansell JP, et al: Changes in collagen composition and cross-links in bone and skin of osteporotic postmenopausal women treated with percutaneous estradiol implants. Obset Gynecol 1994;83:180-183.
34. Aloia JF, Vaswani A, Yeh JK, et al: Calcium supplementation and without hormone replacement therapy in prevent postmenopausal bone loss. Ann Intern Med 1994;120:97-103.
35. Liberman UA, Weiss SR, Bröll J, et al: oral alendronate on bone mineral density and the incidence of fractures in postmenopausl osteoporosis. N Engl J Med 1995;333:1437-1443.
36. Riggs BL, Hodgson SF, O'Fallon WM, et al: Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-809.
37. Gambrell DR Jr: Update on hormone replacement therapy. Am Fam Physician 1992;42(S):87- 96S.
38. Prince RL, Smith M, Dick IM, et al: Prevention of postmenopausal osteoporosis: A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 1991; 325:1189-1195.
39. Lindsay R, Hart DM, MacLean A, et al: Bone response to termination of oestrogen treatment. Lancet 1978;1:1325-1327.
40. Law MR, Wald NJ, Meade TW: Strategies for prevention of osteoporosis and hip fracture. BMJ 1991;303:453-459.
41. Gorsky RD, Koplan JP, Peterson HB, Thacker SH: Relative risks and benefits of long-term estrogen replacement therapy: A decision analysis. Obstet Gynecol 1994;83:161-166.
42. Campbell S, Whitehead M: Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynecol 1977;4:31-47.
43. Ettinger B: Overview of the efficacy of hormonal replacement therapy. Am J Obstet Gynecol 1987;156:1248-1303.
44. Jensen J, Christiansen C: Dose-response and withdrawal effects on climacteric symptoms after hormonal replacement therapy: A placebo-controlled therapeutic trial. Maturitas 1983;5:125-133.
45. Young RL, Kumar NS, Goldzieher JW: Management of menopause when estrogen cannot be used. Drugs 1990;40:220-230.
46. Steingold KA, Laufer L, Chetkowski RJ, et al: Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 1985;61:627-632.
47. Schiff I, Regestein Q, Schinfeld J, Ryan KJ: Interactions of oestrogens and hours of sleep on cortisol. FSH, LH, and prolactin in hypogonadal women. Maturitas 1980;2:179-183.
48. Ditkoff EC, Crary WG, Cristo M, Loba RA: Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991;78:991-995.
49. Bhatia NN, Bergman A, Karram MM: Effects of estrogen on urethral function in women with urinary incontinence. Am J Obstet Gynecol 1989;160:176-181.
50. Fantl JA, Cardozo L, McClish DK: Estrogen therapy in the management of urinary incontinence in postmenopausal women: A meta-analysis: First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1994;83:12-18.
51. Persson I, Adami HO, Bergkvist L, et al: Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study. BMJ 1989;298:147-151.
52. Schiff I, Tulchinsky D, Cramer D, Ryan KJ: Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980;244:1443-1445.
53. Hirvonen E, Malkonen M, Manninen V: Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981;304:560-563.
54. Barrett-Connor E, Wingard DL, Criqui MH: Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited. JAMA 1989;261:2095-2100.
55. Jensen J, Nilas L, Christiansen C: Cyclic changes in serum cholesterol and lipoproteins following different doses of combined postmenopausal hormone replacement therapy. Br J. Obstet Gynaecol 1986;93:613-618.
56. Christiansen C, Riis BJ: Five years with continuous combined oestrogen/progestogen therapy: Effects on calcium metabolism, lipoproteins, and bleeding pattern. Br J Obstet Gynaecol 1990;97:1087-1092.
57. Felson DT, Zhang Y, Hannan MT, et al: The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-1146.
58. Christiansen C, Christensen MS, Transbol I: Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459-461.
59. Henderson BE, Paganini-Hill A, Ross RK: Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-78.
60. Gallagher JC, Kable WT, Goldgar D: Effect of progestin therapy on cortical and trabecular bone; Comparison with estrogen. Am J Med 1991;90:171- 178.
61. Prior JC: Progesterone as a bone-trophic agent. Endocr Rev 1990;11:386-398.
62. Tremollieres FA, Strong DD, Baylink DJ, et al: Progesterone and promegestone stimulate human bone cell proliferation and insulin-like growth factor-2 production. Acta Endocrinologica 1992;126:329-337.
63. Munk-Jensen N, Pors Neilsen S, Obel EB, Bonne Eriksen P: Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: A double-blind placebo controlled study. BMJ (Clin Res Ed) 1988;296:1150-1152.
64. Morrison JC, Martin DC, Blair RA, et al: The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol 1980;138:99-104.
65. Bullock JL, Massey FM, Gambrell RD Jr: Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975;46:165-168.
66. Gambrell RD Jr: Clinical use of progestins in the menopausal patient: Dosage and duration. J Reprod Med 1982;27(suppl):531-538.
67. Albrecht BH, Schiff I, Tulchinshy D, Ryan KJ: Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish meno pausal vasomotor flushes. Am J Obstet Gynecol 1981;139:631-635.
68. Loprinzi CL, Michalak JC, Quella SK, et al: Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347-352.
69. Loprinzi CL, Johnson PA, Jensen M: Megestrol acetate for anorexia and cachexia. Oncology 1992;49:46-49.
70. Loprinzi CL, Michalak JC, Schaid DJ, et al: Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993;11:762-767.
71. Sherwin BB, Gelfand MM: Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985;151:153-160.
72. Burger HG, Hailes J, Nelson J, Menelaus M: Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women. Br Med J (Clin Res Ed) 1987;294:936-37.
73. Sherwin BB, Gelfand MM: The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987;49:397-409.
74. Urman B, Pride SM, Yuen BH: Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstet Gynecol 1991;77:595-598.
75. Westaby D, Ogle SJ, Paradinas JF: Liver damage from long term methyltestosierone. Lancet 1977;2:262-263.
76. Hickok LR, Toomey C, Speroff L: A comparison of esterified estrogens with and without methyl- testosterone: Effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol 1993;82:919-924.
77. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-15, 71-85.
78. Bush TL, Helzlsouer KJ: Tamoxifen for the primary prevention of breast Cancer: A review and critique of the concept and trial. Epidemiol Rev 1993;15:233-243.
79. Nayfield SG, Karp JE, Ford LG, et al: Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991;83:1450-1459.
80. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-856.
81. Love RR, Newcomb PA, Wiebe DA, et al: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with nodenegative breast cancer. J Natl Cancer Inst 1990;82:1327-1332.
82. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC: Contrasting actions of tamoxifen on endometrial and breast tumor growth in athymic mice. Cancer Res 1988;48:812-815.
83. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ 1991;303:435-437.
84. Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989;1:117-120.
85. Mack TM, Pike MC, Henderson BE, Pfeffer RI: Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976;294:1262-1267.
86. Buring JE, Bain CJ, Ehrmann RL: Conjugated estrogen use and risk of endometrial cancer. Am J Epidemiol 1986;124:434-441.
87. Antunes CM, Stolley PD, Rosenshein NB, et al: Endometrial cancer and estrogen use: Report of a large case-control study. N Engl J Med 1979;300:9- 13.
88. Chu J, Schweid AI, Weiss NS: Survival among women with endometrial cancer. A comparison of estrogen users and nonusers. Am J Obstet Gynecol 1982;143:569-573.
89. Horwitz RI, Feinstein AR: Estrogens and endometrial cancer. Responses to arguments and current status of an epidemiologic controversy. Am J Med 1986;81:503-507.
90. Whitehead MI, Fraser D: The effects of estrogens and progestogens on the endometrium: Modern approach to treatment. Obstet Gynecol Clin North Am 1987;14:299-320.
91. Gelfand MM, Ferenczy A: A prospective 1-year study of estrogen and progestin in postmenopausal women: Effects on the endometrium. Obstet Gynecol 1989;74:398-402.
92. London SJ, Colditz GA, Stampfer MJ, et al: Prospective study of relative weight, height, and risk of breast cancer. JAMA 1989;262:2853-2858.
93. Rosner B, Colditz GA, Willett WC: Reproductive risk factors in a prospective study of breast cancer: The nurses' health study. Am J Epidemiol 1994;139:819-835.
94. Ballard-Barbash R, Schalzkin A, Carter CL, et al: Body fat distribution and breast cancer in the Framingham study. J Natl Cancer Inst 1990;82:286- 290.
95. Bernstein L, Henderson BE, Hanisch R, et al: Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 1994;86:1403- 1408.
96. Newcomb PA, Storer BE, Longnecker MP, et al: Lactation and a reduced risk of premenopausal breast cancer. N Engl J Med 1994;330:81-87.
97. Lambe M, Hsieh CC, Trichopoulos D, et al: Transient increase in the risk of breast cancer after giving birth. N Engl J Med 1994;331:5-9.
98. Dickson RB, Bano M, Johnson MD, et al: Regulation of growth factors and protooncogenes in the normal and malignant mammary gland, in Kahn SA, Stancel GM (eds): Protooncogenes and Growth Factors in Steroid Hormone Induced Growth and Differentiation, Boca Raton, Fla, CRC Press, 1994, pp 143-174.
99. Duhik D, Watson PH, Shiu RPC: Estrogen, c-myc, and breast cancer in Kahn SA, Stancel GM (eds): Protooncogenes and Growth Factors in Steroid Hormone Induced Growth and Differentiation, Boca Raton, Fla, CRC Press, 1994, pp 175-191.
100. The Centers for Disease Control Cancer and Steroid Hormone Study: Long-term oral contraceptive use and the risk of breast cancer. JAMA 1983;249:1591-1595.
101. Steinberg KK, Thacker SB, Smith SJ, et al: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-1990.
102. Cobleigh MA, Berris RF, Bush T, et al: Estrogen replacement therapy in breasl cancer survivors: A time for change. JAMA 1994;272:540-545.
103. Dupont WD, Page DL: Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67-72.
104. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, et al. Menopausal hormone replacement therapy and breast cancer: A meta-analysis. Obstet Gynecol 1992;79:286-294.
105. Armstrong BK: Oestrogen therapy after the menopause - Boon or bane? Med J Aust 1988;148:213-214.
106. Hulka BS: Hormone-replacement therapy and the risk of breast cancer. CA Cancer J Clin 1990;40:289-296.
107. Colditz GA, Egan KM, Stampfer MJ: Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-1480.
108. Hoover R, Gray LA Sr, Cole P, Macmahon B: Menopausal estrogens and breast cancer. N Engl J Med 1976;295:401-405.
109. Gambrell RD Jr, Maier RC, Sanders BI: Decreased incidence of breast cancer in post-menopausal estrogen-progestogen users. Obstet Gynecol 1983;62:435-443.
110. Hunt K, Vessey M, McPherson K, Coleman M: Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987;94:620-635.
111. Bergkvist L, Adami HO, Persson I, et al: The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Mod 1989;321:293-297.
112. Mills PK, Beeson WL, Phillips RL, Fraser GE: Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventisls. Cancer 1989;64:591-597.
113. Colditz GA, Stampfer MJ, Willett WC, et al: Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control 1992;3:433-439.
114. Colditz GA, Hankinson SE, Hunter DJ, et al: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
115. Brzezinski A, Peretz T, Mor-Yosef S, Schenker JG: Ovarian stimulation and breast cancer: Is there a link? Gynecol Oncol 1994;52:292-295.
116. Tseng L, Gusberg SB, Gurpide E: Estradiol receptor and 17 beta-dehydrogenase in normal and abnormal human endometrium. Ann N Y Acad Sci 1977;286:190-198.
117. Speroff L: HRT for the woman who has had breast ca? Contemp Obstet Gynecol 1993;38:33-65.
118. DiSaia PJ: Hormone-replacement therapy in patients with breast cancer: A reappraisal. Cancer 1993;71(suppl 4):1490-1500.
119. Voigt LF, Weiss NS, Chu J, et al: Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-277.
120. Staffa JA, Newschaffer CJ, Jones JK, Miller V: Progestins and breast cancer: An epidemiologic review. Fertil Steril 1992;57:473-491.
121. Key TJ, Pike MC: The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer 1988;24:29-43.
122. Clarke CL, Sutherland RL: Progestin regulation of cellular proliferation. Endocr Rev 1990;11:266-301.
123. Gambrell RD Jr: Proposal to decrease the risk and improve the prognosis of breast cancer. Am J Obstet Gynecol 1984;150:119-132.
124. WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Breast cancer and depot-medroxyprogesterone acetate: A multinational study. Lancet 1991;338:833-838.
125. Lippman M, Bolan G, Huff K: The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 1976;36:4595-4601.
126. Allegra JC, Kiefer SM: Mechanisms of action of progestational agents. Semin Oncol 1985;12(suppl 1):3-5.
127. Gompel A, Malet C, Spritzer P, et al: Progestin effect on cell proliferation and 17 beta-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 1986;63:1174-1180.
128. Benghiat A, Cassidy SA, Davidson HE, et al: Megestrol acetate in the treatment of advanced post-menopausal breast cancer. Eur J Surg Oncol 1986;12:43-45.
129. Buller RE: Hormone replacement therapy following gynecologic cancer. Postgrad Obstet Gynecol 1993;13:1-5.
130. Eeles RA, Tan S, Wiltshaw E, et al: Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991;302:259-262.
131. Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL: Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326-330.
132. Lee RB, Burke TW, Park RC: Estrogen replacement therapy following treatment for Stage I endometrial carcinoma. Gynecol Oncol 1990;36:189-191.
133. Baker DP: Estrogen-replacement therapy in patients with previous endometrial carcinoma. Compr Ther 1990;16:28-35.
134. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 1996;45:5-27.
135. Vussilopoulou-Sellin R: Estrogen replacement therapy for breast cancer survivors: Rationale for a prospective, randomized trial. The Female Patient 1993;18:41-48.
136. Miller BA, Feuer EJ, Hankey BF: Recent incidence trends for breast cancer in women and the relevance of early detection: An update. CA Cancer J Clin 1993;43:27-41.
137. Petrek JA, Dukoff R, Rogatko A: Prognosis of pregnancy-associated breast cancer. Cancer 1991;67:869-872.
138. Zemlickis D, Lishner M, Dengendorfer P, et al: Maternal and fetal outcome after breast cancer in pregnancy. Am J Obstet Gynecol 1992;166;781-787.
139. Nugent P, O'Connell TX: Breast cancer and pregnancy. Arch Surg 1985;120:1221-1224.
140. Guinee VF, Olsson H, Moller T, et al: Effect of pregnancy on prognosis for young women with breast cancer. Lancet 1994;343:1587-1589.
141. de la Rochefordiere A, Asselain B, Campana F, et al: Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993;341:1039-1043.
142. Host H, Lund E: Age as a prognostic factor in breast cancer. Cancer 1986;57:2217-2221.
143. Tretli S, Kvalheim G, Thoresen S, Host H: Survival of breast cancer patient diagnosed during pregnancy or lactation. Br J Cancer 1988;58:382-384.
144. Bergkvist L, Adami HO, Persson I, et al: Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989;130:221-228.
145. Bonnier P, Romain S, Giacalone PL, et al: Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995;85:11-17.
146. Vassilopoulou-Sellin R, Zolinski C: Estrogen replacement therapy in women with breast cancer: A survey of patient attitudes. Am J Med Sci 1992;304:145-149.
147. American College of Obstetricians and Gynecologists: Estrogen replacement therapy in women with previously treated breast cancer (ACOG Committee Opinion 135). Washington, DC, ACOG, 1994.
148. Lindsay R: Hormone replacement therapy for prevention and treatment of osteoporosis. Am J Med 1993;95(suppl 5A) 37S-39S.
149. Ryan PJ, Harrison R, Blake GM Fogelman I: Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol 1992;99:325-328.
150. Draper J, Roland M: Perimenopausal women's views on taking hormone replacement therapy to prevent osteoporosis. BMJ 1990;300:786-788.
151. Nachtigall LE: Enhancing patient compliance with hormone replacement therapy at menopause. Obstet Gynecol 1990;75(suppl 4):77S-80S.
152. Ravnikar VA: Compliance with hormone therapy. Am J Obstet Gynecol 1987;156:1332-1334.